WA doctor among those fired in RFK Jr.'s purge of vaccine panel
(Photo by)
Dr. Helen Chu gained attention early in the COVID-19 pandemic as her repurposed flu research project identified the first case of coronavirus spreading person-to-person in the United States.
She and her colleagues carried out this work in defiance of the federal government. And her efforts to accelerate the pandemic response later earned her a 'Washingtonian of the Year' award from a state leadership board.
After a two-year vetting process, the University of Washington scientist landed a spot last year on the federal Centers for Disease Control and Prevention's influential panel of vaccine experts.
But on Monday, Health and Human Services Secretary Robert F. Kennedy Jr. fired Chu and the 16 other members of the Advisory Committee on Immunization Practices.
'I really worry about the health and safety of people in our country and the future of our public health infrastructure,' Chu told reporters Thursday in a call with U.S. Sen. Patty Murray.
Kennedy said he wanted to restore trust in a panel he believed was rife with conflicts of interest.
And on Wednesday, he named eight replacement members, including several with track records criticizing vaccines.
Kennedy himself has a history of promoting skepticism and unfounded theories about vaccines.
He came to Olympia in 2019, for example, to advocate against legislation that would have made it harder for parents to opt their children out of the measles, mumps and rubella shot in the middle of a measles outbreak.
The medical field largely condemned this week's firings.
For over 60 years, the committee has reviewed vaccine efficacy and recommended who should receive which shots. The guidance goes to the CDC director, who usually follows the group's decisions. These recommendations impact what vaccines insurers will cover, as opposed to forcing patients to pay out of pocket.
Members typically serve four-year terms.
The purge comes on the heels of Kennedy announcing unilaterally that federal health officials would stop recommending COVID vaccines for healthy children and healthy pregnant women.
The federal panel is set to meet later this month, with recommendation votes scheduled for several vaccines, including for coronavirus.
'RFK Jr is not just crossing a red line for public health,' said Murray, a Democrat from Washington. 'He is sprinting into dangerous, uncharted territory in support of totally deranged conspiracies, and he is dragging us all along with him.'
Chu used the example of a vaccine against respiratory syncytial virus, or RSV, to show the importance of the committee's work, and that it's not just a rubber stamp for immunizations.
When reviewing data on the proposed vaccine, the panel found a risk of the rare neurological disorder known as Guillain-Barré Syndrome. So Chu, an infectious diseases professor at the UW, and her fellow members decided to recommend the shot only for older adults at a higher risk of getting severe symptoms from RSV.
'I think this example really illustrates the approach that the ACIP takes, that what we do is rooted in science, and that the decisions we make do not necessarily benefit the companies that have invested heavily to develop these vaccines,' Chu said. 'As a result, ACIP is widely regarded as an international gold standard for vaccine decision making.'
Lacking trust in the committee's potential recommendations, Chu advised doctors to turn to groups like the American Academy of Pediatrics and American College of Obstetrics and Gynecology for science-based vaccine guidance.
She worries that turning the previously 'independent, unbiased' committee into something driven by 'one person's beliefs,' Americans will lose trust in national vaccine policy. This could lead to a patchwork of policies that differ state to state, Chu said.
'Washington state is a place where we have experts and scientists who work together,' she said. 'There are other states where this may not exist, or where they may not choose to recommend vaccines, so that is going to create a lot of chaos.'
Murray pleaded with her Republican colleagues in the Senate to tell Kennedy his moves are unacceptable. To get confirmed, Kennedy made concessions to moderate Republicans, namely Sen. Bill Cassidy of Louisiana, over how much he would disrupt existing vaccine policy.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
UCLA study: COVID vaccinations may lessen severe kidney damage
June 13 (UPI) -- A new study from UCLA Health suggests COVID vaccines may protect patients from severe kidney damage. The study found hospitalized COVID patients were less likely to have severe kidney damage if they were vaccinated. UCLA Health researchers found 16% of unvaccinated patients were more likely to need a constant dialysis therapy, compared with 11% of vaccinated patients. The study data came from roughly 3,500 patients admitted to hospitals between March 2020 and March 2022. Study lead author and UCLA nephrology professor Dr. Niloofar Nobakht said the continuous renal replacement therapy (CRRT) form of dialysis is vital for intensive care patients with damaged kidneys. The goal of the study was to asses the severity of kidney injury in COVID patients needing CRRT while hospitalized. According to University of Pennsylvania biostatistics professor Yong Chen, serious kidney complications are typically associated with severe COVID cases. Study participants had received at least two doses of the Pfizer or Moderna mRNA vaccines or one dose of the Johnson & Johnson Janssen vaccine. Yale University Dr. F. Perry Wilson said the main reason vaccinated people have lower kidney injury rates is the vaccines tend to lessen the chances of severe illness. He said the vaccines don't act directly on the kidneys but instead reduce overall illness severity, which in turn helps to prevent complications such as multi-organ failure.


Boston Globe
an hour ago
- Boston Globe
FDA clears Moderna's RSV vaccine for use in people aged 18 to 59
'RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV,' Moderna CEO Stéphane Bancel, said in a statement. Advertisement The approval was a welcome win for the Cambridge-based company, which has faced several setbacks of late due to deep distrust of its messenger RNA vaccine platform among supporters of health secretary Robert F. Kennedy Jr. A number The next step in the vaccine's path to expanded use has already been cleared. At a meeting in April, the Center for Disease Control and Prevention's expert vaccines panel, the Advisory Committee on Immunization Practices, voted to recommend use of RSV vaccine Advertisement At the time of the vote, only two of the three licensed RSV vaccines — Pfizer's Abryso and GSK's Arexvy — were licensed for use in adults under the age of 60. The committee's recommendation was worded in such a way as to include any RSV with a license for use in this age group, so should, in theory, apply as well to the Moderna vaccine now that the age extension has been endorsed by the FDA. But that ACIP recommendation is currently in limbo. A recommendation from the advisory body must be approved by the CDC director or the secretary of the Health and Human Services Department in order to come into force. There is currently no CDC director and in the nearly two months since ACIP endorsed the recommendation, Kennedy has chosen not to sign off on it. He did, however, approve three other recommendations the committee made related to use of chikungunya vaccines. Without a recommendation from the ACIP that has been accepted by the CDC director or the health secretary, the vaccine can be administered to an individual in the new age group, but health insurers do not have to cover its cost. Kennedy Advertisement Late last month Moderna The company said it will have mRESVIA available in the U.S. for both younger adults at increased risk — the ages 18 to 59 cohort — and adults aged 60 and older for the 2025-2026 respiratory virus season.


The Hill
an hour ago
- The Hill
FDA approves expanded use of Moderna's RSV shot, but uncertainty remains
The Food and Drug Administration (FDA) expanded the approval of Moderna's RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness from respiratory syncytial virus, the company said. The vaccine was previously only licensed for adults aged 60 years and older. 'RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV,' Stéphane Bancel, Moderna's CEO, said in a statement. The expanded approval was a much-needed win for the company, which has experienced setbacks due to Trump health officials' distrust of messenger RNA-based (mRNA) vaccines. The Department of Health and Human Services (HHS) recently canceled more than $750 million in contracts for Moderna to develop and test mRNA vaccines to protect against pandemic flu. Moderna's RSV shot was the first non-COVID-19 mRNA vaccine to be approved in the United States. The Centers for Disease Control and Prevention's (CDC) independent vaccine panel, the Advisory Committee on Immunization Practices (ACIP), previously voted to recommend an RSV vaccine for adults aged 50 to 59 who have medical conditions that increase their risk of severe illness from the virus. But the recommendation needs to be endorsed by the CDC director for it to take effect; there currently is no CDC director. Susan Monarez, who had previously been acting director, is awaiting Senate confirmation and isn't allowed to serve as acting director at the same time. HHS Secretary Robert F. Kennedy Jr. has the power to endorse the recommendation in the absence of a CDC director, but he has not signed off on it since the committee voted more than two months ago. He has also not acted on the other recommendations from the same meeting, including the use of a meningitis vaccine. He endorsed the panel's recommendations for chikungunya vaccines in May. Without an officially accepted ACIP recommendation, insurers don't have to cover the vaccine for the expanded population. Kennedy fired all 17 members of ACIP earlier this week, arguing a 'clean sweep' was needed to purge conflicts of interest and help restore trust in vaccinations and public health. On Wednesday, he named eight handpicked replacements, including some vocal vaccine critics. A scheduled late June meeting is still expected to occur.